Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
20.87
+0.28 (1.36%)
Aug 18, 2026, 12:24 PM EDT - Market open
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Cullinan Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $32.36. The average 1-year stock price forecast is 55.06% higher than the current stock price, while the lowest is $23 (+10.21%) and the highest is $42 (+101.25%).
Price Target: $32.36 (+55.06%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $30 | Buy | Reiterates | $30 | +43.75% | Aug 17, 2026 |
| UBS | UBS | Buy Maintains $24 → $27 | Buy | Maintains | $24 → $27 | +29.37% | Aug 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $30 | Buy | Maintains | $30 | +43.75% | Aug 17, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $28 | Buy | Maintains | $28 | +34.16% | Aug 13, 2026 |
| Clear Street | Clear Street | Buy Reiterates $46 → $47 | Buy | Reiterates | $46 → $47 | +125.20% | Aug 13, 2026 |
Financial Forecast
Revenue This Year
13.88M
Revenue Next Year
38.23M
from 13.88M
Increased by 175.49%
EPS This Year
-3.17
from -3.36
EPS Next Year
-2.71
from -3.17
EPS and Forward PE are based on non-GAAP adjusted numbers.